FGN Futuragene

 

TIDMFGN 
 
RNS Number : 9820U 
Futuragene PLC 
02 July 2009 
 

FuturaGene PLC 
2 July 2009 
FUTURAGENE PLC ("FuturaGene" or "the Company") 
Appointment of Dr. Ziv Shani as FuturaGene Group R&D Director 
Appointment of Dr. Nissim Chen as Director, Business Development at CBD 
Technologies, Ltd. 
The Board of FuturaGene, which develops environmentally friendly solutions to 
both enhance crop yields and allow them to grow in hostile conditions, announces 
the appointment of Dr. Ziv Shani, aged 46, as Group R&D Director with immediate 
effect. 
 
 
Dr. Shani is currently VP R&D of CBD Technologies Ltd. ("CBD"), a wholly owned 
subsidiary of the Company, and has held this position since 2006. He joined CBD 
in 1999 and was responsible for the set up and development of the agricultural 
biotech program at CBD, which subsequently developed into the main line of 
activity of CBD. He retains the appointment as VP R&D at CBD. He received his 
B.Sc., M.Sc. and Ph.D. degrees from the Hebrew University of Jerusalem. Dr. 
Shani is a leading contributor to research and development in the field of 
agricultural biotechnology. 
 
 
The Board of FuturaGene also wishes to announce that Dr. Nissim Chen, aged 45, 
has joined CBD in the role of Director, Business Development. Dr. Chen was 
previously Director, Business Development Life Sciences at Ramot, the technology 
transfer company of the University of Tel Aviv and Business Development Manager 
at Lapid Pharmaceuticals Ltd. He received his B.Sc., M.Sc. and Ph.D. degrees 
from the Hebrew University of Jerusalem and he obtained an M.B.A. from 
Tel Aviv University. 
 
 
Mark Pritchard, the Chairman of FuturaGene commented:  "The promotion of Dr. 
Shani recognizes the strong contribution he has made to the development of the 
Group's technology platform and his skill in developing and managing a complex 
R&D program. I believe the appointment of Dr. Chen will add significant momentum 
to the commercialization of our technology portfolio. These new appointments 
represent a substantial strengthening of our management team as we continue to 
move the Group to a new level of development and performance." 
 
 
For further information, please contact: 
FuturaGene Plc 
Mark Pritchard, Chairman                        +44 (0) 7802 827 846 
Stanley Hirsch, CEO                                +972 544 562 724 
Evolution Securities 
Neil Elliot                                                 +44 (0) 20 7071 4300 
Under paragraph g of schedule 2 to the AIM Rules the following information needs 
to be disclosed in respect of Dr Shani: 
Current Directorships: 
FuturaGene Beijing (Consulting) 
Holding in Company 
Dr Shani holds 29,700 ordinary shares of 0.5p each in the capital of the Company 
repsenting 0.63 per cent. of the issued share capital of the Company. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOACKBKPOBKKCOK 
 

Grafico Azioni Futuragene (LSE:FGN)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Futuragene (LSE:FGN)
Storico
Da Giu 2023 a Giu 2024